Geron Corporation — Q2 2012 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2012. Financial statements are unaudited. Geron is a clinical-stage biopharmaceutical company focused on oncology; it reported no product sales and continued to incur operating losses.
Financial results and liquidity
| Metric | Q2 2012 | Q2 2011 | Six months 2012 | Six months 2011 |
|---|---|---|---|---|
| Total revenue | $0.13 million | $0.46 million | $1.38 million | $1.97 million |
| Research and development | $12.78 million | $16.54 million | $27.88 million | $33.30 million |
| General and administrative | $5.83 million | $5.33 million | $10.90 million | $14.44 million |
| Operating loss | $18.48 million | $21.42 million | $37.40 million | $45.77 million |
| Net loss | $18.33 million | $21.09 million | $37.07 million | $45.48 million |
| Net loss per share, basic and diluted | $0.14 | $0.17 | $0.29 | $0.37 |
- Revenue and margins: Revenue was immaterial relative to operating costs; the company reported operating and net losses, so a meaningful positive operating margin was not present. No clear gross-margin figure is provided.
- Cash flow: Six-month operating cash use was $30.35 million, versus $26.75 million a year earlier. Investing activities provided $28.29 million, principally reflecting maturities of marketable securities; financing provided $0.08 million. Cash and cash equivalents declined $1.98 million to $14.12 million.
- Liquidity: Cash, restricted cash, cash equivalents and marketable securities totaled $122.3 million at June 30, down from $154.2 million at December 31, 2011. Current assets were $120.85 million and current liabilities $11.99 million. Management estimated resources, interest income and equipment-facility availability would fund current operations for at least 12 months.
- Debt and obligations: No material borrowing balance is reported in the supplied financial statements. Approximately $0.5 million remained available under an equipment financing facility. Disclosed contractual cash obligations totaled $4.55 million; potential license and collaboration milestones are additional and contingent, including up to $59.9 million in development and $95.0 million in commercial milestones.
Changes versus prior comparable periods
- Six-month net loss narrowed by $8.41 million, mainly because of lower R&D spending after Geron discontinued stem-cell program development and lower non-cash stock-based compensation. Q2 R&D fell $3.77 million year over year; six-month R&D fell $5.42 million.
- Clinical-program spending increased in areas including GRN1005, while reduced personnel and other R&D costs more than offset the increase. Q2 G&A rose year over year, partly due to personnel costs and intellectual-property legal fees; six-month G&A declined, largely due to lower stock-based compensation.
- Revenue decreased, in part because the GE Healthcare collaboration concluded in June 2011. Six-month royalty revenue increased to $0.91 million from $0.76 million, while license-fee revenue declined.
- Liquidity declined by approximately $31.9 million from year-end, reflecting cash used for operations. The accumulated deficit was $822.6 million at June 30.
Outlook, management commentary and key risks
- Clinical programs: Imetelstat was in four Phase 2 trials and GRN1005 in two Phase 2 trials. Enrollment was complete in the randomized imetelstat metastatic breast cancer and non-small-cell lung cancer trials. Geron expected top-line data from the NSCLC trial in Q4 2012, hematologic trials in Q4 2012, the breast cancer trial in Q1 2013, and GRN1005 trials by the end of Q2 2013. These are forward-looking expectations, dependent on clinical events and other factors.
- Spending and capital: Management expected R&D expenses to remain around current levels as the oncology trials continued. It warned that future capital needs were substantial and that additional financing might be required if costs, development plans or timelines changed; financing might not be available on acceptable terms.
- Portfolio changes: Geron had discontinued further development of stem-cell programs and was seeking to divest those assets. Any proceeds were uncertain. The company also commenced winding up its UK subsidiary, completed in August 2012.
- Clinical and execution risks: Trials may be delayed by enrollment, drug supply, vendor or regulatory issues. Enrollment in the multiple myeloma and essential thrombocythemia trials was slower than expected. Imetelstat and GRN1005 had observed dose-limiting toxicities in earlier trials; Phase 2 safety and efficacy remained uncertain. Manufacturing scale, cost, quality and reliance on third parties were material risks.
- Financing and dilution: In July 2012, Geron filed a universal shelf registration statement permitting up to $200 million of securities offerings if declared effective. Future equity issuance could dilute shareholders. The company had no commercially available products and expected continued losses.
- Other matters: No legal proceedings were reported. Management concluded disclosure controls were effective at a reasonable-assurance level; no material change in internal control over financial reporting was reported. Off-balance-sheet arrangements were reported as none.
Important facts for investors to verify
- Whether clinical data and timelines for imetelstat and GRN1005 matched management’s projections, and what the results imply for further development.
- Current cash, marketable securities and operating cash burn, including whether the stated 12-month funding estimate remained valid.
- Whether the $200 million shelf registration became effective and whether Geron subsequently issued securities or incurred dilution.
- Progress and potential proceeds from the planned stem-cell asset divestiture, and any additional restructuring or facility-exit costs.
- Clinical safety, enrollment, manufacturing and third-party supply risks, as well as contingent milestone obligations under license agreements.